There is no shortcut that skips the training: what drugs and peptides can't give you

There is a pattern that runs underneath almost every fitness shortcut, and once you see it you cannot unsee it. A tool produces a result without you. The appetite goes quiet without you deciding to eat less. The soreness fades faster without you doing anything. The number on the scale falls without a single session. It feels like magic because, for a while, it is. And then the pattern completes itself: the tool that produced the result without you tends to stop producing it the moment you stop, and it often costs you something structural on the way - muscle you did not keep, bone you did not load, a habit you never actually built.

This is the flagship of a three-part arc, and it names the whole thing. The first piece looked at what a GLP-1 quietly takes while it takes your appetite. The second looked at what happens when the prescription ends. This one steps back to the general principle behind both, and adds the newer, noisier shortcut that people ask about next: peptides. The honest conclusion is not that any of these tools are bad. Some are genuinely useful and well evidenced. It is that none of them remove the requirement to train, and the training is the one part that compounds and lasts.

This piece is education, not medical advice. It does not tell you to start or stop anything. That decision belongs between you and a qualified clinician, not a fitness blog.

Build the part that lasts with Pocket Fit. The app cannot be your appetite drug or your recovery peptide, but it can be the training that outlives both. Free on the App Store and Google Play, no card needed.

A borrowed result is a result on loan

Think of the difference between renting and owning. A rented result is available immediately and needs no work from you, which is exactly its appeal. But you never hold the deed. The day the payments stop, so does the access, and you walk away with nothing you can keep except whatever you happened to build while you were living there.

An owned result is the opposite. It is slow, it is effortful, and for the first weeks it looks like a worse deal than renting. Then something changes. The adaptations you earned - a stronger back, denser bone, a heart that does more work at a lower cost, a nervous system that has learned a movement - do not switch off when you skip a week. They are written into your tissue. They decay slowly and, as you will see, they come back fast once written. That is ownership.

Every shortcut in this essay is a rental. That is not an insult. Renting is sometimes the right call, and a GLP-1 in particular can be the difference between a decade of failed attempts and finally getting weight off. The mistake is not using the tool. The mistake is believing the rental is the deed, spending the whole tenancy without building anything of your own, and being surprised when the keys go back.

What a GLP-1 genuinely does, and the list it leaves untouched

Start with the tool that actually works, because dismissing it would be dishonest. GLP-1 medications produce large, real weight loss by doing something willpower rarely manages on its own: they turn the food noise down. For many people that is life-changing, and for some it is medically important. This essay is not here to argue anyone off a drug their doctor prescribed.

But look closely at what the weight loss is made of. A meaningful share of what comes off a GLP-1 is not fat - it is lean mass, muscle and connective tissue, the machinery that holds your metabolism up. The two earlier posts in this arc walk through that in detail: how a large slice of the loss is the tissue you did not want to lose (see the muscle you lose on a GLP-1), and how, when people stop, roughly two-thirds of the weight tends to return, mostly as fat, so you can land at a similar weight in worse shape than you started (what happens when you stop a GLP-1).

Now write out the list of things a GLP-1 does not give you, because it is longer than most people expect. It does not build muscle. It does not build strength. It does not add bone mineral density. It does not toughen a tendon. It does not raise your VO2 max or your cardiorespiratory fitness. It does not teach your nervous system a squat or a sprint or the coordination to catch yourself when you trip at seventy. And it does not build the behavioural habit - the thing that keeps any of the above going after the prescription ends. A GLP-1 shrinks you. It does not, on its own, make you stronger, fitter, denser or more durable. Every item on that list is an adaptation, and adaptations are earned, not prescribed.

That is not a criticism of the drug. It is a description of its job. The drug handles appetite. The list above is a different job, and nothing in the injection does it for you.

Peptides: what they promise, and what the evidence actually shows

The next question people ask, once weight is moving, is about the recovery shortcut. Peptides are marketed hard for exactly this: tissue repair, faster healing, better body composition, more growth for less work. The popular names cluster into two groups. There are the tissue-repair peptides, of which BPC-157 and TB-500 are the best known, sold on the promise of healing tendons, ligaments and muscle faster. And there are the growth-hormone secretagogues - class names like the GHRH analogues and the ghrelin-mimetics - sold on the promise of more growth hormone, better recovery and a leaner body.

Here the honest frame matters more than anywhere else in this essay, so hold two things at once. The marketing is confident. The evidence is not there yet. That is not the same as saying these compounds are poison, and it is not the same as saying they work. It is a specific, boring, accurate statement about the state of the science.

Take BPC-157, the most hyped of the group. A 2025 systematic review in the HSS Journal went looking for the human evidence and found the imbalance starkly. Of 36 studies on the peptide in orthopaedic sports medicine, 35 were preclinical - animal or in-vitro - and exactly one involved humans, and that single study was retrospective, not a controlled trial. The authors noted that preclinical safety looked reassuring across several organ systems, then wrote the sentence that actually matters: no clinical safety data were found. There are no published phase 2 or phase 3 randomised controlled trials of BPC-157 in humans for any indication. The rodent data is genuinely interesting. It is also rodent data.

The growth-hormone story is older and, if anything, more cautionary, because there the human trials do exist. A systematic review in the Annals of Internal Medicine pooled 31 randomised controlled trials of growth hormone in healthy older adults - the exact population chasing the anti-ageing promise. Across roughly 500 participants and an average of about six months of treatment, the reviewers found no evidence that it made anyone live longer or function better in any way that justified the trade, alongside a clear signal of harms: joint swelling, carpal tunnel symptoms and a trend toward new diabetes. Secretagogues are a step removed from injected growth hormone, but they are marketed on the same premise those trials failed to support.

Two more facts belong in any honest audit. First, most of these compounds are prohibited in sport: BPC-157 was added to the World Anti-Doping Agency's list in 2022, TB-500 has been banned under the peptide-hormone category since 2018, and growth-hormone secretagogues are prohibited too. Second, and more important for anyone not competing: the supply is unregulated. These are largely research-grade compounds sold through a grey market, which means purity, dose and even the actual contents of the vial are not guaranteed by anyone. You cannot make an informed decision about a substance when you do not reliably know what is in it.

So the peptide verdict is not really a verdict. It is a status report: predominantly preclinical evidence, thin-to-absent long-term human safety data, and a supply chain that guarantees nothing. That is a reason to be cautious, not a reason to panic. And it stands in sharp contrast to the one intervention where the human evidence is not thin at all.

Train the way the evidence supports. Pocket Fit builds the thing every study in this piece is actually measuring: consistent, progressive training you can keep doing. Free on iOS and Android.

Where the evidence runs thin, on every side

Before the case for training, the honest caveats, because they cut in more than one direction.

The GLP-1 body-composition data is real but still maturing: lean-mass loss varies a lot between people, and how much of it matters functionally over decades is not fully settled. The peptide evidence, as above, is mostly preclinical and short, and absence of human trials is not proof of harm any more than it is proof of benefit - it is simply absence.

The training evidence has its own limits, and pretending otherwise would break the whole argument. The mortality findings you are about to read are observational: they show strong, consistent association, not clean proof of cause, because you cannot randomise thousands of people to a decade of lifting versus none. The bone-density trial is small and specific to one population. The muscle-memory work is early molecular biology, not a promise about your particular body. Detraining is real: stop for long enough and strength and fitness do fade.

What tips the balance is not that the training evidence is flawless. It is that it is large, human, long-term, consistent across outcomes, and pointed at the exact adaptations the shortcuts cannot touch. That is a different quality of evidence from a confident rodent study, and it is worth weighting accordingly.

What training uniquely and durably builds

Here is where the ledger flips. The thing that asks the most of you is also the thing with the deepest evidence behind it, and it produces precisely the list a GLP-1 and a peptide leave blank.

Start with staying alive. A systematic review and meta-analysis in the British Journal of Sports Medicine pooled 16 cohort studies on muscle-strengthening activity and hard health outcomes. People who did any strength work had roughly a 10 to 17 percent lower risk of all-cause mortality, along with lower risk of cardiovascular disease, diabetes and total cancer, and the association held independently of aerobic exercise. The dose was almost comically small: the benefit showed up at about 30 to 60 minutes a week, with a J-shaped curve suggesting you do not need much to capture most of it. No peptide has evidence within orders of magnitude of that, because no peptide has been followed across whole populations for years.

Then aerobic fitness, the thing a GLP-1 explicitly cannot raise. A study of 122,007 adults undergoing treadmill testing, published in JAMA Network Open, found cardiorespiratory fitness inversely associated with mortality with no observed ceiling - fitter was always better. The gap between the top performers and the least fit was not subtle: an adjusted hazard ratio of 0.20, an eighty percent lower risk of death, with the authors noting that poor fitness carried risk comparable to or greater than coronary artery disease, diabetes or smoking. You cannot inject that number. You build it, one session at a time.

Then bone, which quietly decides whether the last decades of your life are independent or not. The LIFTMOR randomised controlled trial, published in the Journal of Bone and Mineral Research, took 101 postmenopausal women with low bone mass - exactly the group told for years that heavy lifting was too dangerous for them - and put half through eight months of twice-weekly heavy resistance and impact training. Their lumbar-spine bone density rose about 2.9 percent while the control group lost ground, and physical function improved with it. Loading builds bone. Nothing you swallow or inject reliably does what mechanical load on the skeleton does.

Notice what all three have in common. They are human. They are measured over years or across whole populations. And every one of them is an adaptation - a change your body makes in response to a demand. That is the mechanism the shortcuts route around, and it is exactly why they cannot deliver the result. You do not get the adaptation without the demand.

The one adaptation that stays: muscle memory

The strongest argument for owning rather than renting is what happens when you stop. Detraining is real - miss enough weeks and strength and fitness recede. But they do not reset you to zero, and the reason is now visible at the molecular level.

A study in Scientific Reports was the first in humans to map the genome-wide methylation of muscle through a full cycle: growth, then a return to baseline, then growth again. The finding was that muscle carries an epigenetic memory of having been trained. Specific genes stayed marked for growth even after the muscle had shrunk back toward its starting size during the break, and when training resumed those same muscles grew faster and further the second time. In plain terms: the work you did once is not fully lost when you stop. It leaves a trace that makes the regain quicker than the original gain.

Sit with what that means against the rest of this essay. A borrowed result vanishes when the rental ends - stop the drug and the appetite noise returns, stop the peptide and whatever it was doing stops. A trained result behaves in the opposite way. It fades slowly, it stays partly written into the tissue, and it comes back fast. That asymmetry is the whole case. The shortcut gives you something that leaves completely when you stop paying. The training gives you something that, even after a gap, is still partly yours and quicker to reclaim.

Keep the training going with Pocket Fit. The point of an app is not motivation on your best day; it is the session that still happens on your worst one. Free on iOS and Android.

What to actually do with this

None of this is an argument for purity or against tools. It is an argument for putting the tools in the right order. A practical way to hold it:

• Use the tools that are genuinely evidence-based, as adjuncts. If a GLP-1 is right for you and your clinician, it can do a job willpower struggles with. Let it. Just do not let the easy weeks pass without building anything underneath them.
• Treat unproven shortcuts as unproven. For peptides, the honest position is not fear, it is patience: the human safety and efficacy data is not there yet, and the supply is unregulated. That is reason enough to wait for better evidence before betting your body on it.
• Protect muscle while any weight is coming off. Resistance training plus enough protein is the single most reliable way to keep loss pointed at fat, not lean mass - the mechanism the drug ignores. See progressive overload and protein and training in a calorie deficit.
• Make the training small enough to actually repeat. The mortality benefit showed up at 30 to 60 minutes a week. The barrier is almost never volume; it is consistency, and consistency is a habit problem, not a willpower one. That is where accountability without shame does more than any supplement.

Where Pocket Fit fits

Here is the honest place for the app, and it is a modest one. Pocket Fit is not a drug and does not pretend to be. It cannot quiet your appetite and it will never sell you a vial. What it can do is the one thing on this entire list that actually compounds: the training - made decision-free so it gets done on the days you would otherwise skip.

The app builds you a programme and adapts it week to week from what you log, so progressive overload happens by design rather than guesswork (how the programme is built, and why reps come before weight). The Body budget keeps a running tally of the deposits that matter - your workout, your streak, your sleep, your nutrition - so the durable stuff stays visible instead of invisible. Fuel lets you scan a plate or a barcode and check protein with no red numbers and no shame, which is how you defend muscle while weight moves. The scheduler reshuffles a missed session into the rest of the week instead of dropping it, because the enemy of a trained baseline is the skipped week that becomes a skipped month. And the AI coach rebuilds a session from a sentence when life gets in the way. Sleep sits underneath all of it, because the adaptation is written while you recover (sleep and progressive overload).

That is the whole pitch, and it is deliberately small. The tools out there can help. The training is the part we can actually build for you, and it is the part you keep.

Put it together

The argument is simple enough to hold in one hand. Tools that produce a result without you tend to stop producing it when you stop, and they often cost you something structural on the way. A GLP-1 is a real, useful tool for appetite and weight, and for many people the right one - but it does not build muscle, strength, bone, tendons, cardiorespiratory fitness, coordination or the habit that holds any of it together. Peptides are marketed as shortcuts to recovery and growth and sit on thin human evidence and an unregulated supply. The one intervention with deep, human, long-term evidence for the adaptations people actually want - a tenth to a fifth lower risk of dying early, an eighty percent gap between the fit and the unfit, bone that rebuilds under load, muscle that remembers - is training itself, done consistently, with enough protein and enough sleep.

Use the tools that are genuinely useful. Just understand what they are: adjuncts, never replacements. The training is the only line item that compounds into your sixties and seventies, that keeps you carrying your own shopping and getting off the floor unassisted, that is still partly yours after a break. Everything else is on loan.

Pocket Fit exists because the founder lived the slow version rather than the shortcut. Georgi went from 122 kg to competing at The Yard Games, and the app is built around the ordinary, repeatable training that got him there and the bad weeks that nearly stopped it - not a substance, a habit. You can read that story on our story.

Start with Pocket Fit, free. Build the one thing on the list that is still yours in thirty years. Personalised in minutes on iOS and Android.

Fitness shortcuts: common questions

Do peptides like BPC-157 actually work for recovery?

The honest answer is that we do not yet know in humans. A 2025 systematic review found that of 36 studies on BPC-157 in sports medicine, 35 were animal or in-vitro and only one involved people, and that one was retrospective rather than a controlled trial. There are no published phase 2 or phase 3 randomised trials in humans, and no clinical safety data. The rodent findings are interesting, but interesting in rodents is not the same as proven and safe in you. This is not medical advice; discuss any substance with a qualified clinician.

What can a GLP-1 not do that training does?

A GLP-1 reduces appetite and produces real weight loss, but it does not build muscle, strength, bone density, tendon resilience, cardiorespiratory fitness, coordination or the training habit. Those are all adaptations your body makes in response to a demand, and nothing in the injection supplies the demand. That is why resistance training and protein matter alongside the drug rather than instead of it.

Is training really linked to living longer?

The association is strong and consistent, though observational rather than proof of cause. A meta-analysis of 16 cohort studies found muscle-strengthening activity linked to roughly a 10 to 17 percent lower risk of all-cause mortality, and a study of 122,007 adults found the fittest had about an 80 percent lower mortality risk than the least fit, with no upper ceiling. You cannot randomise people to a decade of training, so these are associations - but they are large, human and repeated across outcomes.

If I stop training, do I lose everything I built?

No. Detraining is real and strength and fitness do fade if you stop for long, but you do not reset to zero. Human muscle carries an epigenetic memory of previous growth, so muscles that were trained before grow back faster and further when you return. A borrowed result disappears when you stop paying for it; a trained one fades slowly and comes back quickly. That asymmetry is the core reason training beats every shortcut over a lifetime.

Is this article telling me to avoid GLP-1s or peptides?

No. This is education, not medical advice, and it does not tell anyone to start or stop anything. GLP-1 medications are legitimate and, for many people, appropriate and even life-changing, and that decision belongs with your doctor. The point is narrower: no tool removes the requirement to train, because the adaptations that last are earned. Use the evidence-based tools as adjuncts, be patient with the unproven ones, and build the training underneath either way.

References

1. Momma H, Kawakami R, Honda T, Sawada SS (2022). Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. British Journal of Sports Medicine, 56(13), 755-763. DOI: 10.1136/bjsports-2021-105061

2. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W (2018). Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Network Open, 1(6), e183605. DOI: 10.1001/jamanetworkopen.2018.3605

3. Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR (2018). High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. Journal of Bone and Mineral Research, 33(2), 211-220. DOI: 10.1002/jbmr.3284

4. Seaborne RA, Strauss J, Cocks M, Shepherd S, O'Brien TD, van Someren KA, Bell PG, Murgatroyd C, Morton JP, Stewart CE, Sharples AP (2018). Human Skeletal Muscle Possesses an Epigenetic Memory of Hypertrophy. Scientific Reports, 8, 1898. DOI: 10.1038/s41598-018-20287-3

5. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 21(4), 485-495. DOI: 10.1177/15563316251355551

6. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (2007). Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly. Annals of Internal Medicine, 146(2), 104-115. DOI: 10.7326/0003-4819-146-2-200701160-00005

---

Pocket Fit is a fitness and wellbeing app, not a medical device. It does not diagnose, treat or prevent any condition. Always consult a qualified healthcare professional before starting or changing a training or nutrition programme, and if you have persistent problems with sleep, pain or fatigue.

Georgi, founder of Pocket Fit. He went from 122 kg to competing at The Yard Games, having lost 38 kg along the way.